Calmare Therapeutics Incorporated (OTCMKTS:CTTC) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01 Changes in Registrant's Certifying Accountant.
On September 7, 2017, Calmare Therapeutics Incorporated (the “Company”), upon the approval of the Audit Committee (the “Committee”) of the Board of Directors of the Company, notified Mayer Hoffman McCann CPAs, the New York Practice of Mayer Hoffman McCann P.C. (“Mayer Hoffman”), the Company’s current independent registered public accounting firm, that it would be dismissed from that position effective immediately.
The audit reports of Mayer Hoffman on the Company’s consolidated financial statements as of and for the years ended December 31, 2016 and 2015 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. During the Company’s two most recent fiscal years ended December 31, 2016 and December 31, 2015, and in the subsequent interim period through September 7, 2017, there were no (1) disagreements with Mayer Hoffman on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Mayer Hoffman, would have caused Mayer Hoffman to make reference to the subject matter of the disagreements in connection with its reports; and (2) events of the type listed in paragraphs (A) through (D) of Item 304(a)(1)(v) of Regulation S-K, except for the material weaknesses reported in the Company’s Annual Report on Form 10-K for the period ended December 31, 2016.
Mayer Hoffman’s report of the consolidated financial statements as of and for the years ended December 31, 2016 and 2015, contained a separate paragraph stating “[as] more fully described in Note 1, the Company has incurred operating losses since fiscal year 2006 and has a working capital and shareholders’ deficit at December 31, 2016. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.”
The Company provided Mayer Hoffman with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (“SEC”) and requested that Mayer Hoffman furnish the Company with a letter addressed to the SEC stating whether or not Mayer Hoffman agrees with the above statements. The letter from Mayer Hoffman is filed with this Current Report on Form 8-K as exhibit 16.1.
On September 13, 2017, the Company, upon the approval of the Committee, appointed BDO USA, LLP (“BDO”) as its new independent registered public accounting firm to audit the Company’s financial statements for the year ending December 31, 2017.
During the Company's fiscal years ended December 31, 2016 and 2015 and the subsequent interim period through September 13, 2017, neither the Company nor anyone on its behalf has consulted with BDO regarding (i) the application of accounting principles to a specific transaction, either completed or proposed or (ii) the type of audit opinion that might be rendered on the Company's financial statements and, neither a written report nor oral advice was provided to the Company that BDO concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issues, or (iii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions), or (iv) any “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).
CALMARE THERAPEUTICS Inc ExhibitEX-16.1 2 s107503_ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 September 14,…To view the full exhibit click here
About Calmare Therapeutics Incorporated (OTCMKTS:CTTC)
Calmare Therapeutics Incorporated (CTI) is a medical device company. The Company is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company offers a portfolio of technologies in life, electronic, nano and physical sciences. The Company’s technology portfolio includes CALMARE pain therapy treatment, neuroprotection and cognitive enhancement, sexual dysfunction therapeutic, skin pigment enhancer, wound sealant, preparation of ordered multi-layer films, silica thin films, structural steel fissure detection paint, public key encryption, growing single crystals, and video compression and moving picture experts group (MPEG)-4. The Company’s subsidiary is Vector Vision, Inc.